TrialThe Journal of infectious diseases2024

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.

Tino F Schwarz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.